Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Synolitic Graph Neural Networks for MRI-Derived Radiomic-Based Prediction of Prostate Cancer Progression on Active Surveillance
0
Zitationen
5
Autoren
2026
Jahr
Abstract
Background: Prostate cancer (PCa) is one of the most prevalent malignancies in men, and active surveillance (AS) is the recommended management strategy for low- and favourable intermediate-risk disease. Predicting which patients will progress during AS remains a clinical challenge. MRI-derived radiomics has shown promise for risk stratification, but conventional machine learning approaches treat radiomic features as independent variables and may not capture the complex inter-feature dependencies within imaging data. This study evaluates the application of Synolitic Graph Neural Networks (SGNNs) to baseline MRI-derived radiomic features for predicting prostate cancer progression on active surveillance. Methods: We studied 343 AS patients (73 progressors, 270 non-progressors) from a single-centre cohort prospectively enrolled between 2013 and 2019 and retrospectively analysed. Seventy-two radiomic features were extracted from baseline 3T MRI (T2-weighted imaging and apparent diffusion coefficient maps), together with three clinical variables (prostate volume, PSA, PSA density). The SGNN pipeline transformed each patient’s feature profile into a weighted graph encoding pairwise feature relationships via logistic regression classifiers trained within each cross-validation fold. GCN and GATv2 architectures were evaluated with multiple sparsification strategies and compared against Gradient Boosting, SVM, Random Forest, and logistic regression using 5-fold stratified cross-validation. Results: Among conventional methods, Gradient Boosting achieved the highest ROC-AUC (0.634 ± 0.080). The SGNN pipeline with GATv2, confidence-based sparsification (p = 0.8), and extended node features incorporating graph centrality measures achieved the best performance (ROC-AUC = 0.699 ± 0.044), an absolute improvement of 0.065 over the best conventional method. The addition of topological node features consistently improved performance by 3–5% across configurations. GATv2 outperformed GCN in matched settings. Conclusions: As a proof of concept, the SGNN framework achieved the highest mean ROC-AUC among the evaluated single-timepoint approaches, though results require confirmation in independent external cohorts. By encoding inter-feature relationships as patient-specific graphs, SGNN offers a complementary modelling paradigm for radiomic data in clinical oncology. Future work should incorporate longitudinal data and graph explainability methods.
Ähnliche Arbeiten
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
2004 · 5.712 Zit.
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
2010 · 5.467 Zit.
Decision Curve Analysis: A Novel Method for Evaluating Prediction Models
2006 · 5.234 Zit.
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
2012 · 4.558 Zit.
Biochemical Outcome After Radical Prostatectomy, External Beam Radiation Therapy, or Interstitial Radiation Therapy for Clinically Localized Prostate Cancer
1998 · 4.503 Zit.